Healing Response to Everolimus-eluting Stent Implantation; Serial Assessment With opticaL Coherence Tomography (HEAL)
|ClinicalTrials.gov Identifier: NCT01689688|
Recruitment Status : Unknown
Verified September 2013 by Toshiro Shinke, MD, PhD, Kobe University.
Recruitment status was: Recruiting
First Posted : September 21, 2012
Last Update Posted : September 9, 2013
|Condition or disease|
|Coronary Heart Disease|
Late and very late stent thrombosis is current main issue after introduction of drug-eluting stents .Possible causes of these stent thromboses include thrombus formation resulting from delayed neointimal coverage, spasms occurring at the distal end of the stent implantation site, positive remodeling of coronary arteries caused by local immune reaction to paclitaxel or rapamycin, and vascular endothelial damage induced by the polymer. For BMS, neointimal coverage begins within the first one month after stent implantation and almost completes in three months. For DES, sirolimus eluting stents (SES) for example, neointimal coverage is markedly delayed after stent implantation and the exposed stent struts may be largely attributable to the occurrence of late stent thrombosis.
On the other hand, everolimus eluting stents (EES), which have a thinner stent strut layer and improved polymer biocompatibility, it has been reported that earlier and more normal neointimal coverage can be achieved compared with other first-generation DESs, SES and paclitaxel eluting stents (PES). These findings suggest that coverage with vascular endothelium differs among different DES platforms. Optical coherence tomography (OCT) has a resolution of 15 to 20 μm, which is approximately 10 times higher than that of intravascular ultrasound (IVUS). It is therefore necessary to use OCT to accurately evaluate cross-sectional images of the stent struts covered with vascular endothelium. However, no studies have reported the results of continuous observation and evaluation of EES covered with endothelium.
Therefore, the investigators investigate time course of neointimal coverage of EES through detailed evaluation by OCT of neointimal coverage at 3, 6, and 12 months after stent implantation.
|Study Type :||Observational|
|Estimated Enrollment :||40 participants|
|Official Title:||Healing Response to Everolimus-eluting Stent Implantation; Serial Assessment With opticaL Coherence Tomography|
|Study Start Date :||September 2012|
|Estimated Primary Completion Date :||September 2013|
|Estimated Study Completion Date :||October 2015|
Groups who were treated with XIENCE V® everolimus eluting stent
- The percentage of neointimal coverage [ Time Frame: 12 months ]The primary endpoint is to evaluate the neointimal coverage of XIENCE everolimus eluting stent (EES) in 12 month after stent implantation by Optical coherence tomography
- The percentage of neointimal coverage [ Time Frame: 3 months ]
- The percentage of neointimal coverage [ Time Frame: 6 months ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01689688
|Kobe University Graduate School of Medicine||Recruiting|
|Kobe, Hyogo, Japan|
|Contact: Toshiro Shinke, MD, PhD +81.78.382.5846 firstname.lastname@example.org|
|Principal Investigator: Toshiro Shinke, MD, PhD|
|Principal Investigator:||Toshiro Shinke||Kobe University Graduate School of Medicine|